The FDA has approved Juvisync, a combination prescription medication for patients with both type 2 diabetes and high cholesterol.
Manufactured by MSD International GmbH Clonmel, Co. in Tipperary, Ireland, Juvisync contains two previously approved medications—sitagliptin and simvastatin—in one tablet. Mary H. Parks, MD, Director of the Division of Metabolism and Endocrinology Products at the FDA, said Juvisync will be available with individual dosages to meet the needs of different patients.
The FDA warned that Juvisync is strictly a combination drug and should only be prescribed for patients in need of both medications. They also stated that while simvastatin is known to increase blood sugar levels in patients with type 2 diabetes, the risks are minimal and are outweighed by the benefits of reduced heart disease.